Press "Enter" to skip to content

New patent expiration for Eisai Inc drug HALAVEN

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Eisai Inc drug HALAVEN

Annual Drug Patent Expirations for HALAVEN
Annual Drug Patent Expirations for HALAVEN

Halaven is a drug marketed by Eisai Inc and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.

This drug has seventy-six patent family members in twenty-seven countries.

The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent expiration for Eisai Inc drug HALAVEN
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions